From Fresh Frozen Plasma to First-in-human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials
Seminars in Thrombosis and Hemostasis · 01.09.2026 · 52 (06) · 746-753
DOI: 10.1055/a-2735-1659 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.09.2026. Verfasst von Jeremy W Jacobs und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee. Hauptthemen laut MEDLINE: Plasma, Factor V Deficiency. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Congenital factor V (FV) deficiency, affecting approximately 1 in 1 million individuals worldwide, remains among the rare bleeding disorders (RBDs) without a licensed factor-specific replacement therapy. While other RBDs have successfully transitioned from plasma-based treatment to approved factor concentrates—exemplified by factor X deficiency's progression to US Food & Drug Administration (FDA)-approved Coagadex and two FDA-approved concentrates for factor XIII deficiency—FV deficiency treatment has remained unchanged for decades, relying solely on plasma and platelet transfusions. Two promising therapeutic candidates have emerged: a human plasma-derived FV concentrate demonstrating in vitro correction of severe deficiency, and an engineered activated FV (superFVa) showing potent hemostatic activity in preclinical models. This commentary outlines a pragmatic pathway to clinical trials, leveraging proven development strategies from other RBDs, existing registry infrastructure, and regulatory incentives for rare diseases. We propose phased trials combining pharmacodynamic endpoints with clinical outcomes, enabling feasible enrollment while generating decision-grade evidence. The time has come to extend modern therapeutic development to FV deficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Transfusion Medicine, Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee.
- Special Coagulation Laboratory, Vanderbilt Medical Laboratories, Nashville, Tennessee.
- Division of Hematology, University of Toronto, Toronto, Ontario, Canada.
- Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.
- Department of Laboratory Medicine and Pathology, Seattle Children's Hospital, Seattle, Washington.
ORCID-Profile: Jeremy W Jacobs
Zitieren
APA
Jacobs, J. W., Raza, S., Figueroa Villalba, C. A., Adkins, B. D., Walker, S. C., Booth, G. S., Sharma, D., & Wheeler, A. P. (2026). From Fresh Frozen Plasma to First-in-human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials. Seminars in Thrombosis and Hemostasis, 52(06), 746-753. https://doi.org/10.1055/a-2735-1659
Vancouver
Jacobs JW, Raza S, Figueroa Villalba CA, Adkins BD, Walker SC, Booth GS, et al. From Fresh Frozen Plasma to First-in-human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials. Seminars in Thrombosis and Hemostasis. 2026;52(06):746-753. doi:10.1055/a-2735-1659
BibTeX
@article{Jacobs2026,
author = {Jacobs, Jeremy W and Raza, Sheharyar and Figueroa Villalba, Cristina A and Adkins, Brian D and Walker, Shannon C and Booth, Garrett S and Sharma, Deva and Wheeler, Allison P},
title = {From Fresh Frozen Plasma to First-in-human: Bringing Coagulation Factor V Deficiency into Therapeutic Trials},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {06},
pages = {746--753},
doi = {10.1055/a-2735-1659}
}
EUVIMED